Polyplus-transfection

Activities: Research & Development Pharmaceutical

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
  3. SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
  4. Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer Denis will be responsible for optimising global operations for the company
  5. SeaBeLife awarded over €1.5 million in i-Nov innovation competition Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

Related Content

Pharmaceutical

Polyplus introduces off-the-shelf plasmids for AAV2 production; plans to expand plasmid portfolio to support full range of AAV serotypes in 2024

Polyplus (part of Sartorius), a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial grade, has launched pPLUS® AAV-RC2, a RepCap plasmid for adeno-associated virus vector 2 (AAV2) production
Regulatory

Polyplus expands GMP offer with protein production and adds GMP capacity in Belgium

Polyplus (part of Satorius) company, Xpress Biologics, has received a good manufacturing practice (GMP) certification for recombinant protein production and renewed the January 2023 GMP certification for DNA production at the facility located in Belgium
Finance

MarkHerz and Polyplus collaborate to advance CGT process standards and lower costs

Polyplus (part of Sartorius) has inked a collaboration with pioneering Korean cell and gene therapy (CGT) CDMO, MarkHerz, to set new CGT efficiency standards focused on decreasing cost and increasing quality per dose of a therapeutic product
Manufacturing

Sartorious to acquire plasmid manufacturer Polyplus

Polyplus develops and produces transfection as well as other DNA/RNA delivery reagents and plasmid DNA in high quality and GMP grade
Manufacturing

Polyplus introduces LipidBrick for LNP formulation in mRNA therapeutics

The cationic lipid broadens the scope of LNP usage in various applications from prophylactic vaccines to therapeutic and oncology applications
Manufacturing

Polyplus announces GMP accreditation for DNA production

This comes after the company acquired Xpress Biologics, a Belgian CDMO
Drug Delivery

Polyplus acquires Xpress Biologics

The acquisition will strategically expand the Polyplus plasmid DNA engineering technology and services portfolio
Subscribe now